诊室采样嗜酸性粒细胞过氧化物酶诊断嗜酸性慢性鼻窦炎
本研究前瞻性纳入42例受试者(31例慢性鼻窦炎患者和11例对照),在诊室鼻内镜下采集中鼻道鼻细胞学刷检样本,用ELISA定量嗜酸性粒细胞过氧化物酶(EPX)水平。慢性鼻窦炎组EPX中位水平为125.0 ng/mL,对照组为6.5 ng/mL(p=0.003)。EPX水平与哮喘史、过敏史、息肉、嗅觉丧失及全身嗜酸性粒细胞增多或IgE升高相关,并与局部组织嗜酸性粒细胞增多及白细胞介素-5水平相关,可能成为区分嗜酸性慢性鼻窦炎的诊断工具。
要点
- 慢性鼻窦炎组EPX中位125.0 ng/mL vs 对照组6.5 ng/mL(p=0.003)。
- 局部组织嗜酸性粒细胞增多者EPX中位967.5 ng/mL vs 无者10.6 ng/mL(p=0.0008)。
- EPX水平与白细胞介素-5水平呈正相关(p=0.0005)。
核心结论
- EPX可通过耐受良好的诊室鼻腔黏液采集进行测量,其水平与2型炎症临床标志物及组织嗜酸性粒细胞增多相关,可能为区分嗜酸性慢性鼻窦炎提供有价值的诊断工具。
研究设计与样本
- 前瞻性纳入就诊于三级医疗鼻科门诊的伴和不伴慢性鼻窦炎受试者,共42例,包括31例慢性鼻窦炎患者和11例对照。
- 在诊室鼻内镜下采集中鼻道鼻细胞学刷检样本,用ELISA定量EPX水平,用定制多重免疫分析定量炎症细胞因子介质,并与临床数据关联。
主要发现
- 慢性鼻窦炎组EPX中位水平为125.0 ng/mL(标准差1745.8),对照组为6.5 ng/mL(标准差99.0),p=0.003。
- EPX水平与哮喘史(p=0.015)、过敏(p=0.028)、息肉(p=0.0006)、嗅觉丧失(p=0.006)及全身嗜酸性粒细胞增多或免疫球蛋白E升高(p≤0.0001)相关。
- 28例来自慢性鼻窦炎组和对照组的受试者有既往病理可供比较,其中11例组织学证实局部组织嗜酸性粒细胞增多(>10个嗜酸性粒细胞/高倍视野),该亚组EPX中位水平为967.5 ng/mL,而无局部组织嗜酸性粒细胞增多的17例为10.6 ng/mL(p=0.0008)。
- EPX水平与白细胞介素-5水平呈正相关(p=0.0005)。
临床怎么用
- 原文结论认为EPX水平与2型炎症临床标志物及组织嗜酸性粒细胞增多相关,可能为区分嗜酸性慢性鼻窦炎提供有价值的诊断工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Practical biomarkers for endotypic characterization of chronic rhinosinusitis (CRS) remain elusive, hindering clinical utility. Eosinophil peroxidase (EPX) is an enzyme released by activated eosinophils. The objective of this study was to evaluate a clinic EPX assay as a marker of eosinophilic CRS. METHODS: Subjects with and without CRS presenting to a tertiary care rhinology clinic were prospectively enrolled, and nasal cytology brushings were collected from the middle meatus during in-clinic nasal endoscopy. ELISA assay was used to quantify EPX levels, and a customized multiplex immunoassay was used to quantify inflammatory cytokine mediators. Findings were correlated with clinical data. RESULTS: Forty-two subjects were enrolled, including 31 CRS subjects and 11 controls. Median EPX levels were 125.0 ng/mL (standard deviation [SD] 1745.8) and 6.5 ng/mL (SD 99.0) for CRS group and controls, respectively (p = 0.003). EPX levels were associated with history of asthma (p = 0.015), allergies (p = 0.028), polyps (p = 0.0006), smell loss (p = 0.006), and systemic eosinophilia or elevated immunoglobulin E (p ≤ 0.0001). Twenty-eight subjects from both the CRS and control groups had prior pathology for comparison, with histologic confirmation of local tissue eosinophilia (>10 eosinophils/hpf) in 11 subjects. This subgroup had a median EPX level of 967.5 ng/mL compared to 10.6 ng/mL in 17 subjects without local tissue eosinophilia (p = 0.0008). EPX levels were positively correlated to interleukin-5 levels (p = 0.0005). CONCLUSION: EPX levels can be measured via well-tolerated in-clinic collection of nasal mucus. EPX levels are associated with clinical markers of type 2 inflammation and tissue eosinophilia and may provide a valuable diagnostic tool to delineate eosinophilic CRS.
引用
- Callander JK, Charbit AR, Khanna K, et al. In office sampling of eosinophil peroxidase to diagnose eosinophilic chronic rhinosinusitis. Int Forum Allergy Rhinol. 2024. PMID: 39269218. doi:10.1002/alr.23448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。